Cva Family Office, LLC Moleculin Biotech, Inc. Transaction History

Cva Family Office, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$0.41 - $0.86 $205 - $430	500 New	500 $0
Q4 2021 Jan 25, 2022	BUY	$1.64 - $2.83 $820 - $1,415	500 New	500 $1,000
Q3 2021 Oct 12, 2021	SELL	$2.7 - $3.59 $1,350 - $1,795	-500 Closed	0 $0
Q1 2021 Apr 14, 2021	BUY	$3.7 - $6.42 $1,850 - $3,210	500 New	500 $2,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Cva Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Cva Family Office, LLC with notifications on news.